Search

Rustum S Boyce

from West Berlin, VT
Age ~59
Get Report
Also known as:
Rustum Sam Boyce, Roshan S Boyce, Sam Boyce Rustum, Oyee V Rustun, Brian D Reitmeyer
Related to:
Dale Manning, 61Delna Boyce, 56
Connected to:
Adrianna M Boyce, 34Alan Boyce, 44Alean C Boyce, 89Alecia M Boyce, 43Angel Boyce, 52Anne-Marie V Boyce, 29Antoinette Boyce, 30Antonio Boyce, 39Ariel Boyce, 34Ashia A Boyce, 34

Rustum Boyce Phones & Addresses

  • West Berlin, VT
  • Mansfield, MA
  • Vacaville, CA
  • Scarsdale, NY
  • San Francisco, CA
  • New York, NY
  • Cambridge, MA

Work

Company: Vermont biosynthetics Sep 2016 to Jul 2019 Position: Chief executive officer

Education

School / High School: Harvard University 1995 to 1997

Skills

Medicinal Chemistry • Drug Discovery • Oncology • Lead Change • Drug Design • Small Molecules • Heterocyclic Chemistry • Parallel Synthesis • Organic Chemistry • Adme • Synthetic Organic Chemistry • Drug Development • Lead Optimization • Organic Synthesis • Life Sciences • Biotechnology • Infectious Diseases • Lc Ms • Purification • Nmr • Chromatography • Licensing • Molecular Biology • Pharmaceutical Industry • Biochemistry • In Vitro

Industries

Biotechnology

Resumes

Resumes

Rustum Boyce Photo 1

St Marys School, Mumbai

View page
Location:
Mansfield, MA
Industry:
Biotechnology
Work:
Vermont Biosynthetics Sep 2016 - Jul 2019
Chief Executive Officer
Vipragen Biosciences Sep 2016 - Jul 2019
Vice President
Vivaldi Biosciences Inc. Jan 2009 - Sep 2011
Director Smdd
Merlion Pharmaceuticals 2006 - 2008
Director of Medicinal Chemistry
Chiron Corporation Apr 1997 - Apr 2005
Principal Scientist
Education:
Harvard University 1995 - 1997
Columbia University In the City of New York 1989 - 1994
Doctorates, Doctor of Philosophy, Organic Chemistry St. Xavier's College
Bachelors, Bachelor of Science, Chemistry Saint Mary's School
Skills:
Medicinal Chemistry
Drug Discovery
Oncology
Lead Change
Drug Design
Small Molecules
Heterocyclic Chemistry
Parallel Synthesis
Organic Chemistry
Adme
Synthetic Organic Chemistry
Drug Development
Lead Optimization
Organic Synthesis
Life Sciences
Biotechnology
Infectious Diseases
Lc Ms
Purification
Nmr
Chromatography
Licensing
Molecular Biology
Pharmaceutical Industry
Biochemistry
In Vitro

Publications

Us Patents

Cyclized Derivatives As Eg-5 Inhibitors

View page
US Patent:
20110003791, Jan 6, 2011
Filed:
Sep 15, 2010
Appl. No.:
12/882473
Inventors:
Rustum Boyce - New York NY, US
Eric Martin - El Cerrito CA, US
Weibo Wang - Moraga CA, US
Hong Yang - Fremont CA, US
Paul A. Barsanti - Pleasant Hill CA, US
International Classification:
A61K 31/553
A61K 31/4178
A61K 31/422
A61K 31/5355
A61K 31/5377
A61K 31/496
A61K 31/551
A61P 35/00
C12N 5/09
US Classification:
51421103, 514397, 514376, 5142288, 5142308, 51425405, 514218, 435375
Abstract:
The present invention relates to new substituted imidazole compounds have the following Formula (I) and to the pharmaceutically acceptable salts, esters, or prodrugs thereof, to compositions of the compounds together with pharmaceutically acceptable carriers, and to uses of the compounds:

Lipopeptide Compounds And Their Use

View page
US Patent:
20110224129, Sep 15, 2011
Filed:
Nov 24, 2009
Appl. No.:
13/128661
Inventors:
Rustum S. Boyce - Scarsdale NY, US
Joseph Cherian - Singapore, SG
Cleofe Calanasan - Singapore, SG
Muhammad Sofian Asi Sihombing - Singapore, SG
International Classification:
A61K 38/12
C07K 7/60
A61P 31/04
US Classification:
514 29, 530318
Abstract:
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain lipopeptide compounds comprising a cyclic peptide bearing a lipid side chain (for convenience, collectively referred to herein as “LP compounds”), which, inter alia, are antimicrobial, particularly antibacterial. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to provide an antimicrobial function, particularly an antibacterial function, and in the treatment of diseases and conditions that are mediated by microbes, particularly bacteria, that are ameliorated by the antimicrobial function, particularly an antibacterial function, including bacterial diseases, optionally in combination with another agent, for example, another antibacterial agent.

Therapeutic Macrolide Compounds And Their Use

View page
US Patent:
20110237566, Sep 29, 2011
Filed:
Nov 24, 2009
Appl. No.:
13/130144
Inventors:
Rustum S. Boyce - Scarsdale NY, US
Muhammad Sofian Asi Sihombing - Singapore, SG
Hiroki Sone - Singapore, SG
Assignee:
MERLION PHARMACEUTICALS PTE LTD - Singapore
International Classification:
A61K 31/553
C07D 313/00
C07D 413/14
C07D 405/14
C07D 267/10
C07D 243/08
A61K 31/336
A61K 31/5355
A61K 31/497
A61K 31/4523
A61K 31/551
A61P 35/00
US Classification:
51421101, 549346, 544147, 544374, 546207, 540544, 540575, 514450, 5142315, 5142541, 514326, 514218
Abstract:
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain macrolide compounds (for convenience, collectively referred to herein as “MC compounds”), which, inter alia, are useful in treatment of cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to treat proliferative conditions such as cancer, and in the treatment of diseases and conditions that are mediated by the regulation (e.g. inhibition) of cell proliferation, optionally in combination with another agent.

Cyclized Derivatives As Eg-5 Inhibitors

View page
US Patent:
20120189623, Jul 26, 2012
Filed:
Apr 3, 2012
Appl. No.:
13/438569
Inventors:
Rustum Boyce - New York NY, US
Eric Martin - El Cerrito CA, US
Weibo Wang - Moraga CA, US
Hong Yang - Fremont CA, US
Paul A. Barsanti - Pleasant Hill CA, US
International Classification:
A61K 39/395
A61K 31/422
A61K 31/5355
A61K 31/5377
C07D 403/06
A61K 31/496
A61K 31/551
A61K 31/553
A61K 33/24
A61K 31/675
A61K 31/7068
A61K 31/704
A61K 31/4745
A61K 31/513
A61K 31/519
A61P 35/00
A61P 35/02
C07D 413/06
US Classification:
4241331, 548231, 514376, 544 96, 5142288, 544139, 5142308, 544370, 51425405, 540492, 514218, 540488, 51421103, 424649, 514110, 514 49, 514 34, 514283, 514274, 514249
Abstract:
The present invention relates to new substituted imidazole compounds have the following Formula (I) and to the pharmaceutically acceptable salts, esters, or prodrugs thereof, to compositions of the compounds together with pharmaceutically acceptable carriers, and to uses of the compounds:
Control profile
Rustum S Boyce from West Berlin, VT, age ~59 Get Report